Victor Amador Diaz

Mr. Victor Amador Diaz

Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2019 in Cancer Research
Verified
Journal Article
Open access
PDF file
EBElizabeth R. Butch
Elizabeth R. Butch
PMPaul E. Mead
Paul E. Mead
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
HTHeather Tillman
Heather Tillman
ESElizabeth Stewart
Elizabeth Stewart
SSScott E. Snyder
Scott E. Snyder
The cell membrane glycolipid GD2 is expressed by multiple solid tumors, including 88% of osteosarcomas and 98% of neuroblastomas. However, osteosarcomas are highly heterogeneous, with many tumors exhibiting GD2 expression on 99%, P < 0.05). These results support the utility of GD2 imaging with PET to measure GD2 expression in osteosarcoma and thus maximize the clinical impact of anti-GD2 immunotherapy. Significance: In situ assessment of all GD2-positive osteosarcoma sites with a novel PET radiotracer could significantly impact anti-GD2 immunotherapy patient selection and enable noninvasive probing of correlations between target expression and therapeutic response.

9 January 2008 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
VGVanessa Gómez
Vanessa Gómez
JGJuan Domingo Gispert
Juan Domingo Gispert
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
JLJordi Llop
Jordi Llop

31 March 2023
Verified
Other
Open access
EBElizabeth R. Butch
Elizabeth R. Butch
PMPaul E. Mead
Paul E. Mead
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
HTHeather Tillman
Heather Tillman
ESElizabeth Stewart
Elizabeth Stewart
SSScott E. Snyder
Scott E. Snyder
The cell membrane glycolipid GD2 is expressed by multiple solid tumors, including 88% of osteosarcomas and 98% of neuroblastomas. However, osteosarcomas are highly heterogeneous, with many tumors exhibiting GD2 expression on <50% of the individual cells, while some tumors are essentially GD2-negative. Anti-GD2 immunotherapy is the current standard of care for high-risk neuroblastoma, but its application to recurrent osteosarcomas, for which no effective therapies exist, has been extremely limited. This is, in part, because the standard assays to measure GD2 expression in these heterogeneous tumors are not quantitative and are subject to tissue availability and sampling bias. To address these limitations, we evaluated a novel, sensitive radiotracer [64Cu]Cu-Bn-NOTA-hu14.18K322A to detect GD2 expression in osteosarcomas (six patient-derived xenografts and one cell line) in vivo using positron emission tomography (PET). Tumor uptake of the radiolabeled, humanized anti-GD2 antibody [64Cu]Cu-Bn-NOTA-hu14.18K322A was 7-fold higher in modestly GD2-expressing osteosarcomas (32% GD2-positive cells) than in a GD2-negative tumor (9.8% vs. 1.3% of the injected dose per cc, respectively). This radiotracer also identified lesions as small as 29 mm3 in a 34% GD2-positive model of metastatic osteosarcoma of the lung. Radiolabeled antibody accumulation in patient-derived xenografts correlated with GD2 expression as measured by flow cytometry (Pearson r = 0.88, P = 0.01), distinguishing moderately GD2-expressing osteosarcomas (32%–69% GD2-positive cells) from high GD2 expressors (>99%, P < 0.05). These results support the utility of GD2 imaging with PET to measure GD2 expression in osteosarcoma and thus maximize the clinical impact of anti-GD2 immunotherapy.Significance:In situ assessment of all GD2-positive osteosarcoma sites with a novel PET radiotracer could significantly impact anti-GD2 immunotherapy patient selection and enable noninvasive probing of correlations between target expression and therapeutic response.

31 March 2023
Verified
Other
Open access
EBElizabeth R. Butch
Elizabeth R. Butch
PMPaul E. Mead
Paul E. Mead
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
HTHeather Tillman
Heather Tillman
ESElizabeth Stewart
Elizabeth Stewart
SSScott E. Snyder
Scott E. Snyder
Combined Supplementary Data file containing: Figure S1-Detailed ex vivo biodistribution data for three additional PDX tumors. Only summary data included in the manuscript Table 1. Figure S2-Multimodality imaging protocol. Figure S3-Ex vivo biodistribution of 64Cu-Bn-NOTA-hu14.18K322A in mice with and without co-injection of a therapeutic dose of unmodified hu14.18K322A to verify non-target binding. Table S1-Summary of multi-modality imaging results for all 8 animals in the osteosarcoma lung metastasis model.

20 December 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
SSScott E Snyder
Scott E Snyder
AVAmy L Vavere
Amy L Vavere
Vacuum pump wear is the most prevalent failure mode of the IBA Synthera® automated radiochemistry system. Rebuilding or replacing the pump causes equipment downtime and increases the radiation exposure of the service personnel. We built a dedicated test device to assess new or rebuilt pumps prior to installation, thus reducing downtime and radiation exposure during repairs. The Testbed incorporates a microprocessor that actuates the pump, valves, pressure sensor, and communicates with the user through lights, buttons, and an alphanumeric screen. The Testbed increases productivity and safety in the radiochemistry laboratory.

6 April 2023 in Instruments
Verified
Journal Article
Open access
PDF file
Victor Amador DiazVictor Amador Diaz
Victor Amador Diaz
SSScott E. Snyder
Scott E. Snyder
AVAmy L. Vavere
Amy L. Vavere
Vacuum pump wear is the most prevalent failure mode of the IBA Synthera® automated radiochemistry system. Rebuilding or replacing the pump causes equipment downtime and increases the radiation exposure of the service personnel. We built a dedicated test device to assess new or rebuilt pumps prior to installation, thus reducing downtime and radiation exposure during repairs. The Testbed incorporates a microprocessor that actuates the pump, valves, and pressure sensor; communicates with the user through lights, buttons, and an alphanumeric screen; and outputs test results to a laptop. The Testbed increases productivity and safety in the radiochemistry laboratory.